D.C. Circuit Says Drug Maker Did Not Show Error In FDA’s Refusal To Reclassify
WASHINGTON, D.C. —The U.S. Food and Drug Administration did not violate the Administrative Procedure Act (APA) by refusing to reclassify a company’s drug as a biological product, which makes approval of...To view the full article, register now.
Already a subscriber? Click here to view full article